Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-07-26
1997-04-01
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 530395, 530397, 530399, A61K 3816
Patent
active
056165544
ABSTRACT:
The present invention relates generally to the fields of immunology and molecular biology, and particularly to a thymus-derived factor which stimulates, enhances or regulates cell-mediated immune responsiveness. In one embodiment, the factor is a substantially homogeneous immune potentiator which stimulates mature T lymphocytes and thus enhances the response of animals, especially mammalian organisms, to infectious agents and to malignancies.
REFERENCES:
patent: 4120951 (1978-10-01), Goldstein
patent: 4571336 (1986-02-01), Houck et al.
patent: 4716148 (1987-12-01), Horecker
patent: 4720482 (1988-01-01), Cantor et al.
patent: 4722998 (1988-02-01), Cantor et al.
patent: 4814434 (1989-03-01), Goldfarb
patent: 4904643 (1990-02-01), Brunetti et al.
patent: 4965195 (1990-10-01), Namen et al.
Ogata, et al. "Thymic Stroma-Derived T Cell Growth Factor (TSTGF) Journal of Immunol." 139:8 pp. 2675-2682, (Oct. 1987).
Waksal, et al. "Induction of T-Cell Differentiation Invitro by Thymus Epithelial Cells" Annals New York Academy of Sciences, pp. 492-498, 1975.
Beardsley, et al. "Induction of T-Cell Maturation by a Cloned Line of Thymic Epithelium (TEPI) Immunology 80:" pp. 6005-6009, (Oct. 1983).
Hays, et al. "Immunologic Effects of Human Thymic Stromal Grafts and Cell Lines" Clin. Immunol and Immunop. 33: pp. 381-390, (1984).
Au Lupin D. et al. "The Prerferential Binding of Immature Thymocytes to a Rat" So Thymus 14(4) Abstract (1989).
Fox, BioTech., vol. 12, p. 128, Feb. 1994.
Meijer et al., Antiviral Res., vol. 18, pp. 215-258, 1992.
Fahey et al., Clin. exp. Immunol., vol. 88, pp. 1-5, 1992.
Martin et al., Cancer Res., vol. 46, pp. 2189-2192, Apr. 1986.
Jain, Scientific American, p. 58, Jul. 1994.
Lane, The New England Jour. of Med., vol. 311 (17), pp. 1099-1103, 1984.
Lane, Annals of Internal Medicine, vol. 103, pp. 714-719, 1985.
Hirsch, The Amer. J. Med., vol. 86 (suppl. 2A), pp. 182-185, 1988.
Osband et al., Immunol. Today, vol. 11(6), pp. 193-195, 1990.
Konrad, "Biological Barrier to Protein Delivery", eds. Audus et al., Plenum Press, pp. 409-437, 1993.
Curti, Crit. Rev. in Oncology/Hematology, vol. 14, pp. 29-39, 1993.
Wedner, Basic & Clin Immunol., Eds Stiles et al., 7th Edition, Appleton & Lange, Chap 34, 1991.
LandOfFree
Immune-enhancing agent for therapeutic use in immunocompromised does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune-enhancing agent for therapeutic use in immunocompromised , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune-enhancing agent for therapeutic use in immunocompromised will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-538857